248 related articles for article (PubMed ID: 28128741)
1. MicroRNA in breast cancer: The association with BRCA1/2.
Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
[TBL] [Abstract][Full Text] [Related]
2. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
4. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
[TBL] [Abstract][Full Text] [Related]
7. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
8. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
Tommasi S; Pinto R; Danza K; Pilato B; Palumbo O; Micale L; De Summa S
Oncotarget; 2016 Dec; 7(49):80363-80372. PubMed ID: 27385001
[TBL] [Abstract][Full Text] [Related]
9. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
[TBL] [Abstract][Full Text] [Related]
10. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
11. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
12. rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility.
Cao J; Luo C; Yan R; Peng R; Wang K; Wang P; Ye H; Song C
Med Oncol; 2016 Dec; 33(12):135. PubMed ID: 27807724
[TBL] [Abstract][Full Text] [Related]
13. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in sporadic triple negative breast cancer.
Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
[TBL] [Abstract][Full Text] [Related]
15. Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Garcia AI; Buisson M; Damiola F; Tessereau C; Barjhoux L; Verny-Pierre C; Sornin V; Dondon MG; Eon-Marchais S; ; Caron O; Gautier-Villars M; Coupier I; Buecher B; Vennin P; Belotti M; Lortholary A; Gesta P; Dugast C; Noguès C; Fricker JP; Faivre L; Stoppa-Lyonnet D; Andrieu N; Sinilnikova OM; Mazoyer S
Eur J Hum Genet; 2016 Aug; 24(9):1324-9. PubMed ID: 26785832
[TBL] [Abstract][Full Text] [Related]
16. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
Abdel-Sater F; Najar M; Fayyad-Kazan H
J Cell Physiol; 2020 Jun; 235(6):5204-5212. PubMed ID: 31736084
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
19. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
